SUN-062 Randomized Controlled Trial for Assessment of the Effects of Anaglipitin, a DPP-4 Inhibitor, on Blood Lipids in Type 2 Diabetic Patients

Background and aims: Dyslipidemia, which is associated with type 2 diabetes, additively increases cardiovascular complications. To date several incretin drugs have been reported to improve lipid metabolism. Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor and has been reported to improve the metabolism of lipid, mainly cholesterol, in the previous studies. The objective of the present study is to examine the effects of treatment with anagliptin on plasma apolipoprotein and cholesterol fraction in patients with type 2 diabetes. Materials and methods: This multicenter, open-label, randomized (1:1), parallel group study was designed to evaluate the effects of anagliptin on plasma apolipoprotein and cholesterol fraction. It was conducted in 24 patients with type 2 diabetes at the two participating hospitals for a period of 24 weeks. Patients were randomly assigned to anagliptin group (n=12) or control group (n=12). Patients in the anagliptin group were treated with anagliptin at 200 mg twice daily. Patients in the control group did not receive anagliptin and continued the previous treatment. Markers of lipid metabolism were measured at baseline and after 24 weeks of administration. Results: Treatment with anagliptin for 24 weeks significantly reduced fast apolipoprotein B-48, which is a marker of food-derived exogenous lipid uptake, compared to control group (-1.4±0.6 µg/ml vs. 0.8±0.6 µg/ml. P<0.05). Adiponectin was significantly increased from baseline in the anagliptin group (7.4±3.7 µg/ml to 8.6±3.9 µg/ml. P<0.05), although no significant difference was observed in the control group. Glycated hemoglobin (HbA1c) was significantly decreased from baseline in the anagliptin group (7.1±0.5% to 6.8±0.6%. P<0.05), although no significant difference was observed in the control group. Conclusion: This study showed that anagliptin reduced fast apolipoprotein B-48 levels as well as HbA1c.